A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
Glossmann
J-P
JP
First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50931 Cologne, Germany.
Josting
A
A
Pfistner
B
B
Paulus
U
U
Engert
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous
D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine